Skip to main content

Table 6 Comparison of Costs Between Floseal® (Baxter, USA)® and Usual Care

From: Management of Persistent Epistaxis Using Floseal Hemostatic Matrix vs. traditional nasal packing: a prospective randomized control trial

 

Control

(N = 13)

Treatment (Floseal)

(N = 13)

Mean

Median (IQR)

Mean

Median (IQR)

Societal erspective

Health System Perspective

Direct disease-related health services (e.g. physician fees, material costs, admission, surgical fees, medications)

$2704.51

(354.71 – 3846.71)

$1136.90

(530.11 – 580.92)

Non-Health Sector Costs

Work productivity losses (e.g. lost wages)

$1342.23

(405.79-1623.16)

$676.32

(405.79-405.79)

Total Costs

$4046.74

(1033.88-5469.87)

$1813.22

(945.10-1164.20)

Differential Mean Costsa (95% CI)b

Health system perspective: -$1567.61 (−3787.25 to 652.00)

Societal perspective: - $2233.36 (−5443.27 to 976.56)

  1. a Floseal® (Baxter, USA) minus control
  2. b 95% non-parametric confidence interval based on 1000 bootstrap replications